Sponsor Dossier
Atnahs Pharma
Sponsor Dossier for Atnahs Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ANAPROX
- Brand: BONDRONAT
- Brand: CRYSANAL
- Brand: DIPENTUM
- Brand: ELOVAX
- Brand: FAMVIR
- Brand: FRISIUM
- Brand: INDERAL
About
Atnahs Pharma is an Australian Private Company with ABN 50169865187, registered in NSW and currently active.
Portfolio
Atnahs Pharma holds 22 brands on the ARTG, of which 21 are indexable. The portfolio includes 20 brands with Product Information on file, 12 brands with at least one PBS-listed item, 5 brands with PBAC outcome records, and 2 brands with AusPAR records. Notable brands include ANAPROX, BONDRONAT, CRYSANAL, DIPENTUM, ELOVAX, FAMVIR, FRISIUM, INDERAL, KYTRIL, LEUSTATIN, NAPROSYN and PROXEN.
Therapeutic focus
— Neurology: 5 brands — Immunology: 4 brands — Oncology: 3 brands — Cardiology: 3 brands — Infectious Disease: 2 brands — Gastroenterology: 2 brands — Endocrinology: 1 brand — Women's Health: 1 brand — Psychiatry: 1 brand
PBS footprint
Twelve brands in the Atnahs Pharma portfolio hold at least one PBS-listed item, with the latest PBS schedule date their portfolio touched being 1 May 2026.
Regulatory activity
The latest PBAC outcome on record for Atnahs Pharma is dated 1 May 2021, covering 5 brands with PBAC outcomes. The latest AusPAR is dated 12 November 2020, with 2 brands holding AusPAR records.